-+ 0.00%
-+ 0.00%
-+ 0.00%

MANNKIND ANNOUNCES FIRST PATIENT ENROLLED IN INHALE-1ST PEDIATRIC STUDY EVALUATING AFREZZA® FOR YOUTH WITH NEWLY-DIAGNOSED TYPE 1 DIABETES (T1D)

Reuters·02/09/2026 11:05:00

Please log in to view news